Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$11.7 million.

  • ImmunityBio's Non Operating Income fell 11238.41% to -$11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$87.9 million, marking a year-over-year increase of 6138.34%. This contributed to the annual value of -$69.5 million for FY2024, which is 6865.98% up from last year.
  • As of Q3 2025, ImmunityBio's Non Operating Income stood at -$11.7 million, which was down 11238.41% from -$21.0 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Non Operating Income peaked at $10.2 million during Q4 2024, and registered a low of -$148.1 million during Q4 2023.
  • Its 5-year average for Non Operating Income is -$25.0 million, with a median of -$15.2 million in 2022.
  • The largest annual percentage gain for ImmunityBio's Non Operating Income in the last 5 years was 42436.59% (2021), contrasted with its biggest fall of 77888.33% (2021).
  • ImmunityBio's Non Operating Income (Quarter) stood at -$12.3 million in 2021, then tumbled by 90.52% to -$23.4 million in 2022, then crashed by 532.97% to -$148.1 million in 2023, then surged by 106.9% to $10.2 million in 2024, then tumbled by 214.26% to -$11.7 million in 2025.
  • Its Non Operating Income was -$11.7 million in Q3 2025, compared to -$21.0 million in Q2 2025 and -$65.5 million in Q1 2025.